Hepatotoxicity and antituberculosis therapy: Time to revise UK guidance?

Thorax

Volumn 64, Issue 10, 2009, Pages 918-

  Walker, N F ^a,b   Kliner, M ^a   Turner, D ^a   Bhagani, S ^a   Cropley, I ^a   Hopkins, S ^a   Lipman, M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS;

EID: 70349675915     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.115469     Document Type: Letter

References (5)

1. American Thoracic Society. An Official ATS Statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952
2. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-548
3. Ahmed AB, Abubakar I, Delpech V, et al. The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999-2003. Thorax 2007;62:672-676
4. Medical Foundation and Sexual Health. Recommended standards for NHS HIV services. 2003. Available at www.medfash.org.uk (accessed 2 Jul 2009).
5. British HIV Association, British Association of Sexual Health and HIV, British Infection Society, UK National Guidelines for HIV Testing 2008. Available at www.bashh.org (accessed 2 Jul 2009).